May 17, 2015 | The Israeli developer of treatments for urinary tract diseases, TheraCoat seeks to raise more than $20 million before it issues its public offering in New York. TheraCoat, which has created a gel technology that allows anti-cancer drugs to stick better to the bladder wall, plans to seek a company valuation of about $200 million in its IPO, which it hopes will take place sometime this year. TheraCoat was founded in 2004 and is headquartered in Ra’anana.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Pineapple-Based Burn Therapy Treating Injured US Troops
October 02, 2023

AI Can Predict Future Heart Attacks By Analyzing CT Scans
October 01, 2023

Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023

Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023
Facebook comments